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Abstract. In the age of bioinformatics and with the advent of high-powered computation over the past decade or so the
landscape of biomedical research has become radically altered. Whereas a generation ago, investigators would study their
“favorite” protein or gene and exhaustively catalog the role of this compound in their disease of interest, the appearance of
omics has changed the face of medicine such that much of the cutting edge (and fundable!) medical research now evaluates
the biology of the disease nearly in its entirety. Couple this with the realization that kidney cancer is a “metabolic disease”
due to its multiple derangements in biochemical pathways [1, 2], and clear cell renal cell carcinoma (ccRCC) becomes ripe
for data mining using multiple omics approaches.
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BODY
It is well known even from what has already been
written in the pages of this new Journal that ccRCC is
a disease which lacks sufficient therapeutic options.
While in the past the search for new chemothera-
pies in cancer (and many other diseases) has been an
exercise in the brute force trial-and-error approach of
new toxic therapies, and sheer luck on the part of the
patient and his/her physician, we now have the abil-
ity to predict what will likely work for each patient’s
disease based on genomics or specific mutational
analysis (as has been the case for several years) and,
more recently, on metabolomics. While mutations
have been targeted in other cancers with a high degree
of success, this has not been the case for ccRCC
and will not be further discussed in this commen-
tary. On the other hand, the discovery largely using
omics technologies of reprogrammed metabolism as
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part and parcel of this metabolic disease has resulted
in several pathways that do not “follow the rules”
and therefore are, or could be, exploited for new ther-
apeutic paradigms with likely far less toxicity than
non-specific brute force therapies. These pathways
will be discussed in some detail later in this article.
Naturally, when discovering and validating novel
or reprogrammed metabolism, the technique most
likely to yield new insights is that of metabolomics as
this field deals with the signatures of essentially all
current and measurable metabolic processes [3, 4]. As
with all omics methods, the practice of metabolomics
(“non-targeted” in its most useful iteration) seeks to
discover all of the small molecule metabolites present
in a given biological system, yet of course just a rel-
atively small fraction of these will actually be found
and chemically identified. After biological validation
(for example in cultured cells or, better, in whole
organisms), those metabolites which are found to be
altered can be studied in the context of their upstream
and downstream neighbors [5]. Once this is done
using in many cases commercially available soft-
ware, established and novel reprogrammed pathways
can be portrayed which will lead, on inspection, to
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pathway convergences or “nodes” conducive to inter-
vention. In many of these cases, on examination of
published lists of small molecules which have been
shown to affect myriad pathways, it can be found that
these pathways have previously been studied and tar-
geted by pharmaceuticals designed for other diseases
and, in many cases, have been long-discarded [6].
For these reasons, it is fair to say that metabolomics
leads to reprogramming insights which result in new
therapeutic targets.
While establishing reprogrammed pathways in
RCC using metabolomics is a very powerful method
with high clinical yield, it is a technique with more
than its share of pitfalls in the main due to the fact that,
with its commercial availability, it is readily avail-
able. Because any investigator in possession of tissue
and/or biofluid samples (and sufficient funding!) can
in theory perform a bare-bones metabolomics study
and thereby generate hypotheses, it is important
before dissemination of the work for the investiga-
tor to biologically validate any findings using in vitro
or in vivo systems lest the findings be later found
to be merely artefactual or of little to no biological
significance. Thus, the proliferation of metabolomics
publications purporting to show novel pathways and
biomarkers need to be evaluated with a very critical
eye and an open mind.
In light of the recent realization that RCC is in
fact a metabolic disease, as discussed above, there
have been a number of well-designed omics stud-
ies using RCC tissue and biofluids showing new and
reprogrammed metabolic pathways (Fig. 1). We sum-
marize the most relevant studies leading to possible
new therapies in the following paragraphs.
Glycolysis
Clear cell RCC (ccRCC) is now well established
to utilize Warburg metabolism. Studies conducted
on ccRCC cells and tissues from mice and patients
using metabolomics [7, 8], proteomics [8–10] and
transcriptomics [11] have shown a strong signa-
ture of increased glycolysis in ccRCC. Levels of
enzymes involved in glycolysis such as hexokinase-1
(HK-1), pyruvate kinase (PK-2) and lactate dehy-
drogenase A (LDH–A) were significantly increased
in ccRCC cells and tissues [9]. While the chemi-
cally modified glucose analog 2- deoxy-D-glucose
(2-DG) acts as substrate to inhibit hexokinase [12],
3-bromopyruvate (3-BrPa) is believed to interfere
directly with HK enzymatic activity and bind to hex-
okinase 2 [13]. In ccRCC, HIF is playing a major
role in activating LDH-A, which is a critical enzyme
in glycolysis. Recent studies targeting HIF using
PT2385 resulted in inhibition of tumor growth in sev-
eral different RCC cell lines [7] and now is being
tested in clinical trials [14].
Fatty acid oxidation and lipid synthesis
Metabolomics studies in ccRCC have revealed
increased utilization of fatty acids [15]. Indeed,
inhibitors of fatty acids oxidation such as PPAR
antagonist was tested in ccRCC models and found
to inhibit tumor growth [16, 17]. In addition, fatty
acid synthase (FASN) which is involved in building
long chain fatty acids and cholesterol was found to be
overexpressed in ccRCC and associated with tumor
aggressiveness and poor prognosis in this disease
[18]. Inhibition of FASN by cerulin or its derivative
C75 induced a rapid increase in malonyl-coA with
a marked reduction in lipogenesis in multiple cancer
models, including RCC cells [19, 20].
Tryptophan
Tryptophan is an essential amino acid and is
catabolized through the kynurenine pathway via
the rate-limited enzyme activity of indoleamine
2,3–dioxygenase (IDO) [21]. One of the most
reported effects of tryptophan metabolism is
immunosuppression as a result of tryptophan
depletion [22] accompanied by an increase in
immunosuppressive metabolites in the kynurenine
pathway [23]. In ccRCC, the level of tryptophan
is reduced, suggesting upregulation of this path-
way leading to immunosuppression [10]. Inhibition
of IDO prevents the purported immunosuppressive
effect and enables T-cell activation in a murine RCC
model [24]. The selective IDO inhibitor epacadostat
was tested in ccRCC and found to enhance the lytic
ability of tumor-antigen-specific T cells in preclinical
models [25].
Glutamine
Several independent studies have shown that glu-
tamine utilization is increased in ccRCC compared
to normal kidney tissues [10, 11, 26]. Target-
ing of enzymes involved in glutamine metabolism,
such as glutaminase (GLS) is being tested. In a
clinical trial, the small molecule inhibitor of glutam-
inase, CB-839, either alone or in combination with
the mTOR inhibitor everolimus, showed favorable
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Fig. 1. Targeting metabolic reprogramming in ccRCC. Glycolysis can be inhibited using inhibitors for hexokinase (HK), the hypoxia-
inducible factor  (HIF-) such as PT2385, Lactate dehydrogenase (LDH-A). Glycolysis can also be inhibited by activators of pyruvate
dehydrogenase kinase-1 (PDK-1), which inhibits pyruvate dehydrogenase (PDH). Fatty acid oxidation can be inhibited using peroxisome
proliferator-activated receptor (PPAR) antagonist (GW-6471). Also fatty acid synthesis can be inhibited using the fatty acid synthase (FASN)
inhibitor TVB-2640. In ccRCC, upregulation of tryptophan metabolism results in increased production of the immunosuppressive metabolites
kynuernine and quinolinate. This pathway can be inhibited using the indoleamine 2,3-dioxygenase (IDO) inhibitor epacadostat. Glutamine
metabolism can be inhibited using the glutaminase (GLS) inhibitor CB-839 and PBTES (Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-
yl)ethyl sulfide).  –KG is  –ketoglutarate. Glutamine is also feeding the glutathione (GSH) pathway. Inhibitors of glutathione peroxidase
(GPX1) and inhibitors of NADPH such as KPT-9274 and FK866 will inhibit changing GSH to GSSG. This reaction is responsible for
scavenging reactive oxygen species (ROS) in the cell. Arginine is synthesized from citrulline in two steps of the urea cycle using the enzymes
argininosuccinate synthase-1 (ASS1), and argininosuccinate lyase (ASL). As ASS1 levels are markedly decreased in all grades of ccRCC, the
tumour cells are dependent on extracellular sources of arginine for their survival. Extracellular arginine can be depleted using the pegylated
form of arginine deaminase enzyme (ADI-PEG20). ASL inhibitors can also be used for targeted therapy of ccRCC.
results in patients with ccRCC [27]. Furthermore glu-
tamine in ccRCC is feeding the glutathione/oxidized
glutathione pathway (GSH/GSSG), an important
pathway for neutralizing ROS in cells [10, 11].
Inhibitors of NADPH synthesis such as KPT-9274
have showed decreased tumor burden in RCC mouse
model [28].
Arginine
Argininosuccinate synthase-1 (ASS1) is the rate-
limiting enzyme for the conversion of citrulline to
arginine for ammonia detoxification through the urea
cycle in the kidney [29]. In ccRCC, ASS1 is not
expressed or is downregulated in tumors [30]. This
finding is confirmed in all ccRCC grades in a pro-
teomic study [9]. Consistent with this model, arginine
deprivation inhibited tumor growth in the RENCA
mouse model of RCC [30]. The pegylated form of
arginine deaminase (ADI-PEG20) can be used to
deplete arginine through deamination of arginine to
citrulline [30, 31].
In summary, the intelligent use of the powerful
technique of metabolomics for discovery and vali-
dation of reprogrammed metabolic pathways in RCC
has thus far resulted in a plethora of new therapeu-
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tic targets for a disease in which they are seriously
lacking. Given that such altered biochemical path-
ways are in most cases confined to the tumor and
not essential for surrounding normal tissue increases
the likelihood that interference with these pathways
by the proposed therapeutic targets will not result in
serious adverse effects. Thus, the stage is now set for
clinical trials of these new compounds either alone
or in combination with established therapies. While
a somewhat high risk venture since in many cases the
function of reprogramming in normal tissues is not
known, the potential gain to the field of this approach
has the potential to be revolutionary and to open up
new therapeutic paradigms.
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